Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

124.70 -0.97 (-0.77%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,073,831
Open 125.52
Bid (Size) 124.26 (5,000)
Ask (Size) 126.18 (300)
Prev. Close 125.67
Today's Range 124.19 - 125.77
52wk Range 88.57 - 128.70
Shares Outstanding 1,253,809,440
Dividend Yield 2.53%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Jobless Claims Unexpectedly Fall For Second Consecutive Week ↗
According to data released by the U.S. Department of Labor on Wednesday, jobless claims fell by 10,000 to 214,000 in the week ended December 20. 
Via Stocktwits
Topics Stocks
News headline image
Repare Therapeutics Stock Rises As Gilead Secures Cancer Asset For $30 Million ↗
Gilead agreed to acquire Repare's RP-3467 cancer drug for up to $30 million, boosting Repare's cash and expected shareholder payout. 
Via Benzinga

Performance

YTD
+35.7%
+35.7%
1 Month
-2.2%
-2.2%
3 Month
+11.2%
+11.2%
6 Month
+12.7%
+12.7%
1 Year
+32.1%
+32.1%

More News

Read More
News headline image
RPTX Stock Soars Pre-Market After Gilead Agrees To Acquire Investigational Cancer Drug ↗
Via Stocktwits
Fitch Sees Stable 2026 Outlook For Global Pharma — But Warns Trump Drug Pricing Push Poses Profit Risk ↗
Via Stocktwits
Topics Government
News headline image
These S&P500 stocks are moving in today's session ↗
Via Chartmill
Assembly Biosciences Stock Jumps After Wall Street Says Gilead Opt-In ‘Significantly De-Risks’ Genital Herpes Programs ↗
Via Stocktwits
News headline image
Gilead Sciences to Present at Upcoming Investor Conference
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Bets On Weekly Pill To Tackle Genital Herpes ↗
Via Benzinga
News headline image
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Trump Secures Drug Price Cuts From 9 Major Pharma Firms Including Bristol Myers, Gilead, Merck In Medicaid Deal ↗
Via Benzinga
Topics Government
News headline image
Why Gilead Sciences (GILD) Stock Is Up Today
Via StockStory
Topics Earnings
News headline image
Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗
Via Stocktwits
Topics Government World Trade
News headline image
Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump ↗
Via Investor's Business Daily
Topics Government Stocks
News headline image
Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Inc. (NASDAQ:GILD): A High-Quality Dividend Stock for Reliable Income ↗
Via Chartmill
News headline image
AbbVie, Merck, Other Top Drugmakers To Lower Prices Of US Drugs In MFN Deal With Trump Administration: Report ↗
Via Stocktwits
Topics Economy Government
News headline image
Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗
Via Stocktwits
Topics Government World Trade
News headline image
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years ↗
Via Benzinga
News headline image
Gilead's Experimental Combo Tablet For HIV Treatment Hits Primary Goal ↗
Via Benzinga
News headline image
3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains ↗
Via MarketBeat
News headline image
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Why Arcus Biosciences Just Reversed Its 287% Eight-Month Winning Streak ↗
Via Investor's Business Daily
News headline image
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
From Equity Insider
Via GlobeNewswire
News headline image
Gilead Sciences Inc. (NASDAQ:GILD) Presents a Compelling Profile for Value Investors ↗
Via Chartmill

Frequently Asked Questions

Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 124.70
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 12/26/25 04:00 PM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 156.35B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 156B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Penticton Herald, Penticton, BC. Powered by BLOX Content Management System from TownNews.com.